消息面上，国家药监局发布2025年度创新医疗器械等产品注册审批情况，2025年，国家药监局按照《创 新医疗器械特别审查程序》《医疗器械优先审批程序》继续做好相关产品的审查工作，共收到创新医疗 器械特别审批申请457项，其中104项获准进入创新医疗器械特别审查程序；收到优先申请38项，其中26 项获准优先审批。 华福证券指出，考虑到医药已调整半年，很充分，继续坚定医药科技主线，26年全年策略如下：1）创 新药：主要三个方向：1、收入和业绩兑现；2、超预期BD兑现的标的；3、前沿技术平台如分子胶、小 核酸、通用/体内CART、基因治疗等弹性主题；2）医疗器械：设备看补库和招投标，如手术机器人和 内镜等，耗材看集采受益的创新耗材如神经介入、外周介入和电生理等方向；3）寻找变化标的：考虑 到中央经济工作会议明确提到26年坚持内需主导，建设强大国内市场，期待内需消费崛起，医药内需相 关公司或将迎来拐点。 医疗创新ETF紧密跟踪中证医药及医疗器械创新指数，中证医药及医疗器械创新指数从医药卫生行业的 上市公司中，选取30只盈利能力较好且具备一定成长性和研发创新能力的上市公司证券作为指数样本， 以反映兼具盈利性与成长性的医药 ...

截至2026年2月26日 09:56，中证医药及医疗器械创新指数(931484)成分股方面涨跌互现，新和成领涨 4.59%，爱博医疗上涨2.03%，锦波生物上涨0.40%；惠泰医疗领跌。医疗创新ETF(516820)最新报价0.36 元。 从资金净流入方面来看，医疗创新ETF近3天获得连续资金净流入，最高单日获得617.32万元净流入， 合计"吸金"1269.71万元，日均净流入达423.24万元。（数据来源：Wind） 消息面上，2026年，中国创新药对外BD交易（商务拓展交易）持续升温、势头强劲。医药魔方 NextPharma数据库显示，截至2月25日，年内中国创新药已发生44起对外授权（license-out）交易事件， 首付款约为31.23亿美元，总金额达532.76亿美元。 江海证券指出，2026年中国创新药BD呈现三大转型：技术输出联合产品授权、平台化合作、全球并跑 创新。建议关注小核酸（递送技术/慢病管线）、肿瘤免疫（双抗/ADC联用）、代谢疾病（GLP-1改良 品种/MASH肝靶向siRNA）、CGT（体内基因编辑/通用型CAR-T）等核心赛道，重点评估平台造血能 力（如年输出管线数）、临床里 ...

截至2026年2月25日 13:49，中证医药及医疗器械创新指数(931484)上涨0.71%，成分股三生国健上涨 8.16%，浙江医药上涨4.83%，南微医学上涨3.45%，新和成上涨2.80%，康龙化成上涨2.16%。医疗创新 ETF(516820)上涨0.55%，最新价报0.36元。 医药板块结构性机会持续深化，AI医疗与脑机接口成为短期主线。消息面上，常州市第一人民医院门 诊大厅内，两个人形机器人"智能导诊员"正式上岗。它们不仅具备预检分诊、信息查询等功能，还能与 患者握手互动，让就医更高效、更有温度。 中信建投证券认为，春节前后A股脑机接口板块部分个股大幅上涨，港股手术机器人公司亦因中标进展 获正面催化；叠加恒瑞医药IL-15疗法启动NMIBC三期、亚盛医药BTK PROTAC进入美国一期临床、和 铂医药新一代CTLA-4抗体通过NewCo出海等密集管线进展，创新药械"从0到1"逻辑正从前端研发向临 床验证与商业化环节传导，AI驱动的靶点发现、药物设计及智能诊疗设备有望成为中长期核心赛道。 医疗创新ETF紧密跟踪中证医药及医疗器械创新指数，中证医药及医疗器械创新指数从医药卫生行业的 上市公司中，选取 ...

数据显示，截至2026年1月30日，中证医药及医疗器械创新指数(931484)前十大权重股分别为药明康 德、迈瑞医疗、恒瑞医药、爱尔眼科、片仔癀、新和成、华东医药、康龙化成、艾力斯、甘李药业，前 十大权重股合计占比63.9%。 截至2026年2月25日 10:27，中证医药及医疗器械创新指数(931484)上涨0.25%，成分股三生国健上涨 3.33%，新和成上涨2.33%，爱博医疗上涨1.73%，特宝生物上涨1.71%，浙江医药上涨1.08%。医疗创新 ETF(516820)上涨0.55%，最新价报0.36元。 从估值层面来看，医疗创新ETF跟踪的中证医药及医疗器械创新指数最新市盈率（PE-TTM）仅27.28 倍，处于近1年18.88%的分位，即估值低于近1年81.12%以上的时间，处于历史低位。 医疗创新ETF紧密跟踪中证医药及医疗器械创新指数，中证医药及医疗器械创新指数从医药卫生行业的 上市公司中，选取30只盈利能力较好且具备一定成长性和研发创新能力的上市公司证券作为指数样本， 以反映兼具盈利性与成长性的医药及医疗器械上市公司证券的整体表现。 消息面上，普华永道（PwC）称，和Anthropic宣布达 ...

数据显示，截至2026年1月30日，中证医药及医疗器械创新指数(931484)前十大权重股分别为药明康 德、迈瑞医疗、恒瑞医药、爱尔眼科、片仔癀、新和成、华东医药、康龙化成、艾力斯、甘李药业，前 十大权重股合计占比63.9%。 风险提示：基金有风险，投资需谨慎。基金管理人承诺以诚实信用、勤勉尽责的原则管理和运用基金资 产，但不保证本基金一定盈利，也不保证最低收益。基金管理人提醒投资人基金投资的"买者自负"原 则，在做出投资决策后，基金运营状况与基金净值变化引致的投资风险，由投资人自行负担。基金的过 往业绩及其净值高低并不预示其未来业绩表现，基金管理人管理的其他基金的业绩不构成对本基金业绩 表现的保证。投资人购买基金，既可能按其持有份额分享基金投资所产生的收益，也可能承担基金投资 所带来的损失。投资人应当认真阅读《基金合同》《招募说明书》等基金法律文件，全面认识本基金的 风险收益特征和产品特性，并根据自身的投资目的、投资期限、投资经验、资产状况等判断基金是否和 投资人的风险承受能力相适应，理性判断市场，谨慎做出投资决策。本材料中相关信息来源于基金管理 人认为可靠的公开资料，相关观点、评估和预测仅反映当前的判断， ...

Core Viewpoint - The medical device sector is experiencing a turning point, driven by performance recovery and innovation in overseas markets, with a focus on surgical robots, brain-computer interfaces, AI medical technology, and high-potential innovative devices like PFA, RDN, and TAVR [1] Group 1: Market Performance - As of February 24, 2026, the CSI Medical and Medical Device Innovation Index (931484) rose by 0.25%, with notable increases in component stocks such as Aier Eye Hospital (up 2.23%), Yingke Medical (up 1.96%), and Xingqi Eye Medicine (up 1.45%) [1] - The Medical Innovation ETF (516820) is currently in a state of market tension, with the latest quote at 0.36 yuan [1] Group 2: Industry Developments - Recent developments in the surgical robot sector, including successful bids from MicroPort Robotics and Aikang Medical, have significantly raised market expectations for the commercialization of related equipment [1] - Continued funding interest in cutting-edge areas such as AI medical technology and brain-computer interfaces is noted, alongside a U.S. court ruling that deemed tariff policies illegal, further strengthening the logic for medical device exports [1] Group 3: Index Composition - As of January 30, 2026, the top ten weighted stocks in the CSI Medical and Medical Device Innovation Index include WuXi AppTec, Mindray Medical, and Hengrui Medicine, collectively accounting for 63.9% of the index [2]

Group 1 - The core viewpoint of the news highlights the mixed performance of the constituents of the CSI Pharmaceutical and Medical Device Innovation Index, with Pizhou Pharmaceutical leading the gains at 1.08% and Xinhengcheng leading the losses [1] - The Medical Innovation ETF (516820) is currently priced at 0.36 yuan, with a turnover rate of 0.63% and a transaction volume of 11.7 million yuan during the trading session [1] - Over the past month, the average daily transaction volume of the Medical Innovation ETF reached 62.8 million yuan [1] Group 2 - Brain Tiger Technology has successfully implanted a fully wireless brain-computer interface in its first clinical patient, who can now perform daily activities such as shopping and sending red envelopes through thought control [1] - According to Jiao Yin International Securities, the pharmaceutical industry is expected to continue shifting towards innovative drugs and high clinical value products due to ongoing medical insurance cost control and centralized procurement [1] - The market sentiment has improved, and significant business development transactions are driving strong performance in the pharmaceutical sector, with a stable outlook expected to continue into 2026 despite potential short-term volatility [1] Group 3 - The CSI Pharmaceutical and Medical Device Innovation Index consists of 30 publicly listed companies with good profitability, growth potential, and research innovation capabilities, reflecting the overall performance of profitable and growth-oriented pharmaceutical and medical device companies [2] - As of January 30, 2026, the top ten weighted stocks in the index include WuXi AppTec, Mindray Medical, and Hengrui Medicine, accounting for a total of 63.9% of the index [2]

Group 1 - The core viewpoint of the news highlights the performance of the China Securities Pharmaceutical and Medical Device Innovation Index, with Zhejiang Medicine leading the gains at 1.43% and Xinhecheng experiencing the largest decline [1] - The Medical Innovation ETF (516820) has a latest price of 0.36 yuan, with a turnover rate of 0.28% and a transaction volume of 5.138 million yuan during the trading session [1] - Over the past month, the average daily transaction volume of the Medical Innovation ETF reached 62.8359 million yuan, indicating strong market interest [1] Group 2 - Recently, Eli Lilly's drug, Migalastat, received approval from the National Medical Products Administration of China for two formulations to treat moderate to severe active Crohn's disease and ulcerative colitis, marking a significant advancement in targeted therapies for autoimmune diseases in the digestive system [1] - According to CMB International, the pharmaceutical industry is experiencing structural differentiation due to medical insurance cost control and normalized centralized procurement, with resources increasingly concentrating on innovative pharmaceutical and medical device companies with technological barriers [1] - Since Q4 2025, both domestic and foreign institutions have been increasing their positions in the innovative pharmaceutical and medical device supply chain, reflecting a clearer market logic for allocating innovative assets with clinical value and overseas potential [1] Group 3 - The China Securities Pharmaceutical and Medical Device Innovation Index (931484) selects 30 publicly listed companies with good profitability, growth potential, and research innovation capabilities to reflect the overall performance of the pharmaceutical and medical device sector [2] - As of January 30, 2026, the top ten weighted stocks in the index include WuXi AppTec, Mindray Medical, Heng Rui Medicine, Aier Eye Hospital, and others, accounting for a total of 63.9% of the index [2]

Core Viewpoint - The medical innovation sector is experiencing growth, highlighted by the successful debut of China's first fully self-developed orthopedic surgical robot, indicating advancements in medical technology and potential investment opportunities in the sector [1][2]. Group 1: Market Performance - As of February 12, 2026, the CSI Medical and Medical Device Innovation Index (931484) increased by 0.05%, with notable gains from companies such as WuXi AppTec (up 3.39%) and Kanglong Chemical (up 1.37%) [1]. - The Medical Innovation ETF (516820) is currently priced at 0.37 yuan, with a trading volume of 794.40 million yuan and a turnover rate of 0.42% [1]. - Over the past month, the average daily trading volume of the Medical Innovation ETF was 65.14 million yuan [1]. Group 2: Industry Insights - CITIC Securities believes that surgical robots represent one of the best business models in the medical device sector, as installed equipment will drive continuous consumption of consumables, leading to stable revenue and cash flow [2]. - The global market for surgical robots is estimated to exceed 1 trillion yuan, with significant growth potential in penetration rates and market size [2]. - Domestic leaders in the surgical robot market are accelerating product iterations, achieving performance levels close to global leaders, and have a substantial portion of their revenue from overseas markets, which are experiencing high growth [2]. - AI is expected to empower surgical robots to achieve autonomous operations, further assisting or replacing some surgical procedures performed by doctors, which will benefit industry penetration rates and enhance company valuations [2]. Group 3: Index Composition - The CSI Medical and Medical Device Innovation Index comprises 30 publicly listed companies with strong profitability, growth potential, and research innovation capabilities, reflecting the overall performance of the medical and medical device sector [2]. - As of January 30, 2026, the top ten weighted stocks in the index include WuXi AppTec, Mindray Medical, and Heng Rui Medicine, collectively accounting for 63.9% of the index [2].

Group 1 - The core viewpoint of the news is that the Chinese medical device and equipment trading platform has been launched in Tianjin, which aims to facilitate global trade in medical devices and equipment, thereby promoting the export of domestic medical products and enhancing cross-border industrial cooperation [1] - The China International Medical Equipment and Instrument Trading Platform will provide services such as online display of pharmaceutical products, procurement information, policy information collection and publication, and market operation data analysis [1] - The medical industry is experiencing a new high due to the continuous demand for pharmaceuticals and the increasing unmet needs, along with pharmaceutical companies increasing their R&D investments to meet these demands [1] Group 2 - The CSI Medical and Medical Device Innovation Index (931484) has shown a positive performance, with a 0.34% increase, and notable gains in constituent stocks such as Teva Bio and New Hope [1] - The top ten weighted stocks in the CSI Medical and Medical Device Innovation Index account for 63.9% of the index, including companies like WuXi AppTec, Mindray Medical, and Hengrui Medicine [2] - The medical innovation ETF closely tracks the CSI Medical and Medical Device Innovation Index, reflecting the overall performance of profitable and growth-oriented medical and medical device companies [2]